Oncostatin M Promotes Mammary Tumor Metastasis to Bone and Osteolytic Bone Degradation

Genes and Cancer

Volumn 3, Issue 2, 2012, Pages 117-130

  Bolin, Celeste ^a   Tawara, Ken ^a   Sutherland, Caleb ^a   Redshaw, Jeff ^a   Aranda, Patrick ^a   Moselhy, Jim ^a   Anderson, Robin ^b   Jorcyk, Cheryl L ^a  

^a BOISE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

bone metastasis; breast cancer; oncostatin M; OSM; osteoclastogenesis; osteolysis

Indexed keywords

AMPHIREGULIN; INTERLEUKIN 6; ONCOSTATIN M; OSTEOPROTEGERIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BONE DEFECT; BONE MASS; BONE METASTASIS; BREAST CANCER; CANCER INVASION; COCULTURE; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR PROMOTION;

MUS;

EID: 84869832364     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912458284     Document Type: Article

References (61)

1. Jemal A,Siegel R,Xu J,Ward E.Cancer statistics, 2010.CA Cancer J Clin. 2010;60 (5): 277-300.
2. Coleman RE.Skeletal complications of malignancy.Cancer. 1997;80 (8 Suppl): 1588-94.
3. Tumminello FM,Badalamenti G,Incorvaia L,Fulfaro F,D'Amico C,Leto G.Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.Med Oncol. 2009;26 (1): 10-5.
4. Heinrich PC,Behrmann I,Haan S,Hermanns HM,Muller-Newen G,Schaper F.Principles of interleukin (IL)-6-type cytokine signalling and its regulation.Biochem J. 2003;374 (Pt 1): 1-20.
5. Korzus E,Nagase H,Rydell R,Travis J.The mitogen-activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression.J Biol Chem. 1997;272 (2): 1188-96.
6. Liu J,Hadjokas N,Mosley B,Estrov Z,Spence MJ,Vestal RE.Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells.Cytokine. 1998;10 (4): 295-302.
7. Hurst SM,McLoughlin RM,Monslow J, et al.Secretion of oncostatin M by infiltrating neutrophils: regulation of IL-6 and chemokine expression in human mesothelial cells.J Immunol. 2002;169 (9): 5244-51.
8. Badache A,Hynes NE.Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.Cancer Res. 2001;61 (1): 383-91.
9. Liu J,Spence MJ,Wallace PM,Forcier K,Hellstrom I,Vestal RE.Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene.Cell Growth Differ. 1997;8 (6): 667-76.
10. Horn D,Fitzpatrick WC,Gompper PT, et al.Regulation of cell growth by recombinant oncostatin M.Growth Factors. 1990;2 (2-3): 157-65.
11. Mori S,Murakami-Mori K,Bonavida A.Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor.Anticancer Res. 1999;19 (2A): 1011-5.
12. Li QH,Zhu JH,Sun F,Liu L,Liu XX,Yue Y.Oncostatin M promotes proliferation of ovarian cancer cells through signal transducer and activator of transcription 3.Int J Mol Med. 2011;28 (1): 101-8.
13. Holzer RG,Ryan RE,Tommack M,Schlekeway E,Jorcyk CL.Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: role of cyclooxygenase-2.Clin Exp Metastasis. 2004;21 (2): 167-76.
14. Jorcyk CL,Holzer RG,Ryan RE.Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells.Cytokine. 2006;33 (6): 323-36.
15. Argast GM,Mercado P,Mulford IJ, et al.Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-beta enhances epithelial to mesenchymal transition in lung and pancreatic tumor models.Cells Tissues Organs. 2010;193 (1-2): 114-32.
16. Hui W,Rowan AD,Richards CD,Cawston TE.Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo.Arthritis Rheum. 2003;48 (12): 3404-18.
17. Fossey SL,Bear MD,Kisseberth WC,Pennell M,London CA.Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.BMC Cancer. 2011;11:125.
18. Soldi R,Graziani A,Benelli R, et al.Oncostatin M activates phosphatidylinositol-3-kinase in Kaposi's sarcoma cells.Oncogene. 1994;9 (8): 2253-60.
19. Crichton MB,Nichols JE,Zhao Y,Bulun SE,Simpson ER.Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells.Mol Cell Endocrinol. 1996;118 (1-2): 215-20.
20. Queen MM,Ryan RE,Holzer RG,Keller-Peck CR,Jorcyk CL.Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression.Cancer Res. 2005;65 (19): 8896-904.
21. Celis JE,Gromov P,Cabezon T, et al.Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery.Mol Cell Proteomics. 2004;3 (4): 327-44.
22. Levano KS,Jung EH,Kenny PA.Breast cancer subtypes express distinct receptor repertoires for tumor-associated macrophage derived cytokines.Biochem Biophys Res Commun. 2011;411 (1): 107-10.
23. Ooi LL,Zheng Y,Stalgis-Bilinski K,Dunstan CR.The bone remodeling environment is a factor in breast cancer bone metastasis.Bone. 2011;48 (1): 66-70.
24. Palmqvist P,Persson E,Conaway HH,Lerner UH.IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.J Immunol. 2002;169 (6): 3353-62.
25. Sims NA,Walsh NC.GP130 cytokines and bone remodelling in health and disease.BMB Rep. 2010;43 (8): 513-23.
26. Song HY,Jeon ES,Kim JI,Jung JS,Kim JH.Oncostatin M promotes osteogenesis and suppresses adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells.J Cell Biochem. 2007;101 (5): 1238-51.
27. Minehata K,Takeuchi M,Hirabayashi Y, et al.Oncostatin m maintains the hematopoietic microenvironment and retains hematopoietic progenitors in the bone marrow.Int J Hematol. 2006;84 (4): 319-27.
28. Tanaka M,Hirabayashi Y,Sekiguchi T,Inoue T,Katsuki M,Miyajima A.Targeted disruption of oncostatin M receptor results in altered hematopoiesis.Blood. 2003;102 (9): 3154-62.
29. O'Connor JC,Farach-Carson MC,Schneider CJ,Carson DD.Coculture with prostate cancer cells alters endoglin expression and attenuates transforming growth factor-beta signaling in reactive bone marrow stromal cells.Mol Cancer Res. 2007;5 (6): 585-603.
30. Knowles HJ,Athanasou NA.Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF.J Pathol. 2008;215 (1): 56-66.
31. Walker EC,McGregor NE,Poulton IJ, et al.Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice.J Clin Invest. 2010;120 (2): 582-92.
32. Sloan EK,Anderson RL.Genes involved in breast cancer metastasis to bone.Cell Mol Life Sci. 2002;59 (9): 1491-502.
33. Rose AA,Siegel PM.Breast cancer-derived factors facilitate osteolytic bone metastasis.Bull Cancer. 2006;93 (9): 931-43.
34. Lelekakis M,Moseley J,Martin T, et al.A novel orthotopic model of breast cancer metastasis to bone.Clin Exp Metastasis. 1999;17 (2): 163-70.
35. Aslakson CJ,Miller FR.Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor.Cancer Res. 1992;52 (6): 1399-405.
36. Grant SL,Begley CG.The oncostatin M signalling pathway: reversing the neoplastic phenotype?.Mol Med Today. 1999;5 (9): 406-12.
37. Akhurst RJ,Derynck R.TGF-beta signaling in cancer: a double-edged sword.Trends Cell Biol. 2001;11 (11): S44-51.
38. Kozlow W,Guise TA.Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy.J Mammary Gland Biol Neoplasia. 2005;10 (2): 169-80.
39. Cicek M,Iwaniec UT,Goblirsch MJ, et al.2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo.Cancer Res. 2007;67 (21): 10106-11.
40. O'Brien CA,Gubrij I,Lin SC,Saylors RL,Manolagas SC.STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone.J Biol Chem. 1999;274 (27): 19301-8.
41. Whitehead KA,Dahlman JE,Langer RS,Anderson DG.Silencing or stimulation? siRNA delivery and the immune system.Annu Rev Chem Biomol Eng. 2011;2:77-96.
42. Jackson AL,Bartz SR,Schelter J, et al.Expression profiling reveals off-target gene regulation by RNAi.Nat Biotechnol. 2003;21 (6): 635-7.
43. Colucci S,Brunetti G,Rizzi R, et al.T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction.Blood. 2004;104 (12): 3722-30.
44. Roato I,Grano M,Brunetti G, et al.Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement.FASEB J. 2005;19 (2): 228-30.
45. Roato I,Gorassini E,Brunetti G, et al.IL-7 modulates osteoclastogenesis in patients affected by solid tumors.Ann N Y Acad Sci. 2007;1117:377-84.
46. Tay JY,Bay BH,Yeo JF,Harris M,Meghji S,Dheen ST.Identification of RANKL in osteolytic lesions of the facial skeleton.J Dent Res. 2004;83 (4): 349-53.
47. Iguchi H,Yokota M,Fukutomi M, et al.A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma.J Exp Clin Cancer Res. 2002;21 (3): 309-13.
48. Naugler WE,Karin M.The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer.Trends Mol Med. 2008;14 (3): 109-19.
49. Kumta SM,Huang L,Cheng YY,Chow LTC,Lee KM,Zheng MH.Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions.Life Sci. 2003;73 (11): 1427-36.
50. Willmarth NE,Ethier SP.Amphiregulin as a novel target for breast cancer therapy.J Mammary Gland Biol Neoplasia. 2008;13 (2): 171-9.
51. Qi CF,Liscia DS,Normanno N, et al.Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas.Br J Cancer. 1994;69 (5): 903-10.
52. Panico L,D'Antonio A,Salvatore G, et al.Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues.Int J Cancer. 1996;65 (1): 51-6.
53. Gilmore JL,Scott JA,Bouizar Z, et al.Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells.Breast Cancer Res Treat. 2008;110 (3): 493-505.
54. Lu X,Wang Q,Hu G, et al.ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis.Genes Dev. 2009;23 (16): 1882-94.
55. Morrison C,Mancini S,Cipollone J,Kappelhoff R,Roskelley C,Overall C.Microarray and proteomic analysis of breast cancer cell and osteoblast co-cultures: role of osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis.J Biol Chem. 2011;286 (39): 34271-85.
56. Beerli RR,Hynes NE.Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities.J Biol Chem. 1996;271 (11): 6071-6.
57. Chanda D,Isayeva T,Kumar S, et al.Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.Mol Ther. 2008;16 (5): 871-8.
58. Aranda PS,LaJoie DM,Jorcyk CL.Bleach gel: a simple agarose gel for analyzing RNA quality.Electrophoresis. 2012;33 (2): 366-9.
59. Bakewell SJ,Nestor P,Prasad S, et al.Platelet and osteoclast beta3 integrins are critical for bone metastasis.Proc Natl Acad Sci U S A. 2003;100 (24): 14205-10.
60. Eckhardt BL,Parker BS,van Laar RK, et al.Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix.Mol Cancer Res. 2005;3 (1): 1-13.
61. Livak KJ,Schmittgen TD.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method.Methods. 2001;25 (4): 402-8.